Explore the impactful findings from the Advocate 1 & 2 clinical trials that establish Ebglyss (Lebrikizumab) as a powerful treatment for moderate-to-severe Atopic Dermatitis (AD). The trials demonstrate how Ebglyss Starts Strong, Lasts Long, and Maintains Monthly delivering sustained relief through targeted IL-13 inhibition. Learn how Ebglyss achieves Clear or almost-clear skin & Early meaningful itch reduction1
